The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents

AKGÜL, Kadir Turgay; GERMİUANOĞLU, Rüştü Cankon; HURİ, Emre; YÜCEL, Mehmet Özgür; Üstün, Hüseyin; astarcı, hesna müzeyyen

The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents

Emre HURİ, (Ankara Eğitim ve Araştırma Hastanesi, 2. Üroloji Kliniği, Ankara, Türkiye)

Kadir Turgay AKGÜL, (Ankara Eğitim ve Araştırma Hastanesi, 2. Üroloji Kliniği, Ankara, Türkiye)

Mehmet Özgür YÜCEL, (Ankara Eğitim ve Araştırma Hastanesi, 2. Üroloji Kliniği, Ankara, Türkiye)

Hesna Müzeyyen ASTARCI, (Sağlık Bakanlığı, Ankara Eğitim ve Araştırma Hastanesi, Patoloji Kliniği, Ankara, Türkiye)

Hüseyin ÜSTÜN, (Sağlık Bakanlığı, Ankara Eğitim ve Araştırma Hastanesi, Patoloji Kliniği, Ankara, Türkiye)

Rüştü Cankon GERMİUANOĞLU (Ankara Eğitim ve Araştırma Hastanesi, 2. Üroloji Kliniği, Ankara, Türkiye)

Turkish Journal of Medical Sciences

1 0

Yıl: 2011 Cilt: 41 Sayı: 1 Sayfa Aralığı: 7 - 15 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents

Öz:

Amaç: Bu çalışmada Ankaferd BloodStopper’ın etkinliği diğer hemostatik ajanlar ile karşılaştırılarak yapılmaya çalışılmıştır. Yöntem ve gereç: Kırk Wistar rat beş gruba ayrıldı. Bu gruplar: T grubu (traditional), hilar kontrol ile parsiyel nefrektomi yapılan, G grubu (Glubran 2) konvansiyonel parsiyel nefrektomi sonrası Glubran 2 uygulanan, F grubu eksize edilen böbrek alanına FloSeal uygulanan, C grubu hemostatik ajan olarak Celox kullanılan, A grubu ise yeni bir hemostatik ajan olan Ankaferd (Ankaferd-ABS) kullanılan gruplar olarak belirlendi. Sıcak iskemi süreleri ve hemostaz zamanları kayıt edildi. Gruplar arasındaki histopatolojik özellikler karşılaştırıldı. Istatistiksel analiz için Kruskal-Wallis ve Mann-Whitney U testleri kullanıldı. Bulgular: A grubunda ölçülen sıcak iskemi süresi anlamlı derecede düşük olarak saptanırken diğer gruplarla fark anlamlı idi (P < 0,001). A grubunda T grubuyla karşılaştırıldığında azalan hemostaz zamanın diğer gruplarla karşılaştırıldığında artmış olduğu belirlendi (P < 0,001). A grubunda diğer gruplarla karşılaştırıldığında anlamlı derecede fibrozis, adhezyon ve kalsifikasyon oluşmadığı gözlendi. F grubunda fibrozis ve adhezyonun artmış olduğu gösterildi. A, F ve G gruplarında eritrosit agregasyonu ve mikrovasküler proliferasyonun anlamlı olarak yüksek olduğu gözlendi (P < 0,001). Sonuç: Yeni çıkan bir hemostatik ajan olan Ankaferd, diğer lisanslı hemostatik ajanlar kadar etkilidir, sıcak iskemi süresi ve hemostaz süreleri için karşılaştırılabilir ve histopatolojik olarak da iyi sonuçlara sahiptir.

Anahtar Kelime:

Konular: Cerrahi

Ankaferd bloodstopper ikinci basamak in vitro çalışması: Diğer hemostatik ajanlarla karşılaştırma

Öz:

Aim: To investigate the efficacy of Ankaferd Bloodstopper (ABS) and compare ABS with the other hemostatic agents still used in urologic surgery. Materials and methods: Forty Wistar rats were divided into 5 groups: Group T (traditional), partial nephrectomy (PN) with hilar control as per the conventional technique; Group G (Glubran 2), conventional PN followed by the application of Glubran 2; Group F (FloSeal), FloSeal application to the resected area of the kidney; Group C (Celox), Celox was applied; Group A (ABS), Ankaferd was used. Warm ischemia time (WIT) and hemostasis time (HT) were recorded and histopathologic features were compared among the groups. Results: In Group A, a significant decrease in WIT was detected while the difference was significant (P < 0.001). Statistical analysis confirmed that the evaluation of HT (in seconds) returned similar results to those seen in WITs among all groups. In Group A, decreased HT was confirmed in comparison to Group T while HT increased in comparison to the other groups (G, C, and F) (P < 0.001). Increased fibrosis and adhesion were shown in Group F while significant erythrocyte aggregation and microvascular proliferation were observed in Groups G, F, and A (P < 0.001). Conclusion: A novel hemostatic agent, ABS, is as effective as other licensed hemostatic agents with comparable WIT and HT and better results in terms of histopathologic findings.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Huri E, Akgül T, Ayyıldız A, Üstün H, Germiyanoğlu C. Hemostatic role of a folkloric medicinal plant extract in a rat partial nephrectomy model: controlled experimental trial. J Urol 2009; 181: 2349-54.
2. Leibovich BC, Blute ML, Cheville JC, Lohse CM., Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004; 171: 1066-70.
3. Gill IS, Desai MM, Kaouk JH, Meraney AM, Murphy DP, Sung GT, et al. Laparoscopic partial nephrectomy for renal tumor: Duplicating open surgical techniques. J Urol 2002; 167: 469-76.
4. Van Dijk JH, Pes PL. Haemostasis in laparoscopic partial nephrectomy: current status. Minim Invasive Ther Allied Technol 2007; 16: 31-44.
5. Msezane LP, Katz MH, Gofrit ON, Shalhav AL, Zorn KC. Haemostatic agents and instruments in laparoscopic renal surgery. J Endourol 2008; 22: 403-8
6. Pasticier G, Timsit MO, Badet L, De La Torre Abril L, Halila M, Fassi Fehri H et al. Nephron-sparing surgery for renal cell carcinoma: detailed analysis of complications over a 15-year period. Eur Urol 2006; 49: 485- 90.
7. Bergel S. Ueber wirkungen des fibrins. Dtsch Med Wochenschr. 1909; 35: 633-65.
8. Radosevich M, Goubran H, Burnouf T. Fibrin sealant: scientific rationale, production methods, properties and current clinical use. Vox Sang 1997; 72: 133-43.
9. Donaldson A, Jackman S. Hand assisted laparoscopic (HAL) heminephrectomy in pigs utilizing AFAB. J Endourol 2002; 16: A20.
10. Ramakumar S, Roberts W, Fugita O, Colegrove P, Nicol TM, Jarrett TW et al. Local hemostasis during laparoscopic partial nephrectomy using biodegradable hydrogels: initial porcine experience. J Endourol 2002; 16: 489-94.
11. Ogan K, Jacomides L, Saboorian H, Koeneman K, Li Y, Napper C, Hoopman J et al. Sutureless laparoscopic heminephrectomy using laser tissue soldering in the porcine model. J Endourol 2003; 17; 295-300.
12. Göker H, Haznedaroğlu IC, Erçetin S, Kirazlı S, Akman U, Öztürk Y et al. Haemostatic actions of the folkloric medicinal plant extract Ankaferd BloodStopper ®. J Int Med Res. 2008; 36: 163-70.
13. Manikandan R, Srinivasan V, Rané A. Which is the real gold standard for small-volume renal tumors? Radical nephrectomy versus nephron-sparing surgery. J Endourol 2004; 18: 39-44.
14. Bak JB, Singh A, Shekarriz B. Use of gelatin matrix thrombin tissue sealant as an effective hemostatic agent during laparoscopic partial nephrectomy. J Urol 2004; 171: 780-82.
15. Germiyanoğlu C, Huri E, Akgül T, Ayyıldız A., Üstün H. In vivo haemostatic effect of Ankaferd Blood Stopper® in rat major renal trauma model: controlled trial of novel haemostatic agent. Int J Hematology and Oncology. 2009, in press
16. Huri E, Akgul T, Ayyildiz A, Germiyanoglu C. Hemostasis in retropubic radical prostatectomy with Ankaferd BloodStopper: a case report. Kaohsiung J Med Sci 2009; 25: 445-47.
17. Hong YM, Loughlin KR. The use of hemostatic agents and sealants in urology. J Urol 2006; 176: 2367-74.
18. Gill IS, Ramani AP, Spaliviero M, Xu M., Finelli A, Kaouk JH. Improved hemostasis during laparoscopic partial nephrectomy using gelatin matrix thrombin sealant. Urology 2005; 65: 463-66.
19. Dalpiaz O, Neururer R, Bartsch G, Peschel R. Haemostatic sealants in nephron-sparing surgery: what surgeons need to know. BJU Int 2008; 102: 1502-08.
20. Johnston WK, Hollenbeck BK, Daignault S, Wolf JS Jr. Acute integrity of closure for partial nephrectomy: comparison of 7 agents in a hypertensive porcine model. J Urol 2006; 175: 2307-11.
21. Kozen BG, Kircher SJ, Henao J, Godinez FS, Johnson AS. An alternative hemostatic dressing: comparison of CELOX, HemCon, and QuickClot. Acad Emerg Med 2008; 15: 74-81.

APA	HURİ E, AKGÜL K, YÜCEL M, astarcı h, Üstün H, GERMİUANOĞLU R (2011). The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. , 7 - 15.
Chicago	HURİ Emre,AKGÜL Kadir Turgay,YÜCEL Mehmet Özgür,astarcı hesna müzeyyen,Üstün Hüseyin,GERMİUANOĞLU Rüştü Cankon The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. (2011): 7 - 15.
MLA	HURİ Emre,AKGÜL Kadir Turgay,YÜCEL Mehmet Özgür,astarcı hesna müzeyyen,Üstün Hüseyin,GERMİUANOĞLU Rüştü Cankon The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. , 2011, ss.7 - 15.
AMA	HURİ E,AKGÜL K,YÜCEL M,astarcı h,Üstün H,GERMİUANOĞLU R The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. . 2011; 7 - 15.
Vancouver	HURİ E,AKGÜL K,YÜCEL M,astarcı h,Üstün H,GERMİUANOĞLU R The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. . 2011; 7 - 15.
IEEE	HURİ E,AKGÜL K,YÜCEL M,astarcı h,Üstün H,GERMİUANOĞLU R "The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents." , ss.7 - 15, 2011.
ISNAD	HURİ, Emre vd. "The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents". (2011), 7-15.

APA	HURİ E, AKGÜL K, YÜCEL M, astarcı h, Üstün H, GERMİUANOĞLU R (2011). The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. Turkish Journal of Medical Sciences, 41(1), 7 - 15.
Chicago	HURİ Emre,AKGÜL Kadir Turgay,YÜCEL Mehmet Özgür,astarcı hesna müzeyyen,Üstün Hüseyin,GERMİUANOĞLU Rüştü Cankon The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. Turkish Journal of Medical Sciences 41, no.1 (2011): 7 - 15.
MLA	HURİ Emre,AKGÜL Kadir Turgay,YÜCEL Mehmet Özgür,astarcı hesna müzeyyen,Üstün Hüseyin,GERMİUANOĞLU Rüştü Cankon The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. Turkish Journal of Medical Sciences, vol.41, no.1, 2011, ss.7 - 15.
AMA	HURİ E,AKGÜL K,YÜCEL M,astarcı h,Üstün H,GERMİUANOĞLU R The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. Turkish Journal of Medical Sciences. 2011; 41(1): 7 - 15.
Vancouver	HURİ E,AKGÜL K,YÜCEL M,astarcı h,Üstün H,GERMİUANOĞLU R The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents. Turkish Journal of Medical Sciences. 2011; 41(1): 7 - 15.
IEEE	HURİ E,AKGÜL K,YÜCEL M,astarcı h,Üstün H,GERMİUANOĞLU R "The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents." Turkish Journal of Medical Sciences, 41, ss.7 - 15, 2011.
ISNAD	HURİ, Emre vd. "The second step in vitro trial of Ankaferd® Bloodstopper®: Comparison with other hemostatic agents". Turkish Journal of Medical Sciences 41/1 (2011), 7-15.